Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia

Complementary Therapies in Medicine

Volumn 35, Issue , 2017, Pages 140-144

  Tshongo Muhindo, Christian ^a   Ahn, Sylvie A ^b   Rousseau, Michel F ^b   Dierckxsens, Yvan ^c   Hermans, Michel P ^d  

^a CATHOLIC UNIVERSITY OF BUKAVU   (Democratic Republic Congo)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Tilman SA ZI Sud   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cholesterol; Diabetes; Hydroxytyrosol; Myalgia; Olive; Red yeast rice

Indexed keywords

APOLIPOPROTEIN B100; CHOLESFYTOL; CHOLESTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLANT EXTRACT; TRIACYLGLYCEROL;

ADULT; ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MYALGIA; OBSERVATIONAL STUDY; OLIVE; TABLET; AGED; BLOOD; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FRUIT; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; OLIVE TREE; PHYTOTHERAPY;

AGED; BIOLOGICAL PRODUCTS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; FRUIT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYALGIA; OLEA; PHYTOTHERAPY; PLANT EXTRACTS; TRIGLYCERIDES;

EID: 85033403200     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2017.10.014     Document Type: Article

References (38)

1. CTT-Cholesterol treatment trialists’ (CTT) Collaborators, Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
2. LaRosa, J.C., Grundy, S.M., Waters, D.D., et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005), 1425–1435.
3. Costa, J., Borges, M., David, C., Vaz Carneiro, A., Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006), 1115–1118.
4. CTT-Cholesterol treatment trialists’ (CTT) Collaborators, Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008), 117–125.
5. Brugts, J.J., Yetgin, T., Hoeks, S.E., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ, 338, 2009, B2376.
6. European Association for Cardiovascular Prevention, Rehabilitation, Reiner, Z., et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (2011), 1769–1818 [addendum II].
7. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
8. Cannon, C.P., Blazing, M.A., Giugliano, R.P., et al. Califf RM; IMPROVE-IT investigators: ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
9. Hermans, M.P., Ahn, S.A., Rousseau, M.F., Effect of lipid management on coronary heart disease risk in patients with diabetes. McGuire, Darren K., Marx, Nikolaus, (eds.) Diabetes in cardiovascular disease: a companion to Braunwald's heart disease, 2015, Elsevier Saunders, 181–202.
10. Wang, T.H., Lin, T.F., Monascus rice products. Adv Food Nutr Res 53 (2007), 123–159.
11. Barbagallo, C.M., Cefalù, A.B., Noto, D., Averna, M.R., Role of nutraceuticals in hypolipidemic therapy. Front Cardiovasc Med, 11(2), 2015, 22.
12. Verhoeven, V., Van der Auwera, A., Van Gaal, L., et al. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind, placebo controlled randomized trial. BMC Complement Altern Med, 15, 2015, 52.
13. Cicero, A.F., Derosa, G., Parini, A., et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 33 (2013), 622–628.
14. Sahebkar, A., Serban, M.C., Gluba-Brzózka, A., et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition 32 (2016), 1179–1192.
15. Cicero, A.F., Derosa, G., Borghi, C., Red yeast rice and statin-intolerant patients. Am J Cardiol, 105, 2010, 1504.
16. Patel, J., Martin, S.S., Banach, M., Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother 17 (2016), 1497–1507.
17. Rosenson, R.S., Baker, S., Banach, M., et al. Optimizing Cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol 70 (2017), 1290–1301.
18. Cicero, A.F.G., Colletti, A., Bajraktari, G., et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci 13 (2017), 965–1005.
19. Efentakis, P., Iliodromitis, E.K., Mikros, E., Papachristodoulou, A., Dagres, N., Skaltsounis, A.L., Andreadou Effects of the olive tree leaf constituents on myocardial oxidative damage and atherosclerosis. Planta Med 81 (2015), 648–654.
20. Banach, M., Rizzo, M., Toth, P.P., et al. Statin intolerance – an attempt at a unified definition: position paper from an International Lipid Expert Panel. Expert Opin Drug Saf 14 (2015), 935–955.
21. Stroes, E.S., Thompson, P.D., Corsini, A., et al. Ginsberg HN; european atherosclerosis society consensus panel statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J 36 (2015), 1012–1022.
22. Hermans, M.P., Ahn, S.A., Rousseau MF. log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Cardiovasc Diabetol, 9, 2010, 88.
23. 100 in patients with T2DM. Cardiovasc Diabetol, 12, 2013, 39.
24. Hattori, Y., Suzuki, M., Tsushima, M., et al. Development of approximate formula for LDL-chol, LDL-apo B and LDL-chol/LDL-apo B as indices of hyperapobetalipoproteinemia and small dense LDL. Atherosclerosis 138 (1998), 289–299.
25. Wagner, A.M., Jorba, O., Rigla, M., Alonso, E., Ordonez-Llanos, J., Perez, A., LDLcholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol 39 (2002), 215–220.
26. Palmer, M.K., Nicholls, S.J., Lundman, P., Barter, P.J., Karlson, B.W., Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur J Prev Cardiol 20 (2013), 1080–1087.
27. Ambegaonkar, B.M., Tipping, D., Polis, A.B., Tomassini, J.E., Tershakovec, A.M., Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysi. Atherosclerosis 237 (2014), 829–837.
28. Nicholls, S.J., Brandrup-Wognsen, G., Palmer, M., Barter, P.J., Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 105 (2010), 69–76.
29. Hermans, M.P., Ahn, S.A., Rousseau, M.F., The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: comparison with reference lipid markers. Diab Metab Syndr 1 (2007), 23–28.
30. Parhofer, K.G., Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J 39 (2015), 353–362.
31. Bulotta, S., Celano, M., Lepore, S.M., Montalcini, T., Pujia, A., Russo, D., Beneficial effects of the olive oil phenolic components oleuropein and hydroxytyrosol: focus on protection against cardiovascular and metabolic diseases. J Transl Med, 3(12), 2014, 219.
32. Hu, T., He, X.W., Jiang, J.G., Xu, X.L., Hydroxytyrosol and its potential therapeutic effects. J Agric Food Chem 62 (2014), 1449–1455.
33. Dugani, S.B., Akinkuolie, A.O., Paynter, N., Glynn, R.J., Ridker, P.M., Mora, S., Association of lipoproteins, insulin resistance, and rosuvastatin with incident type 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA Cardiol 1 (2016), 136–145.
34. Li, Y., Jiang, L., Jia, Z., et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One, 9, 2014, e98611.
35. Priore, P., Caruso, D., Siculella, L., Gnoni, G.V., Rapid down-regulation of hepatic lipid metabolism by phenolic fraction from extra virgin olive oil. Eur J Nutr 54 (2015), 823–833.
36. Lockyer, S., Rowland, I., Spencer, J.P., Yaqoob, P., Stonehouse, W., Impact of phenolic-rich olive leaf extract on blood pressure, plasma lipids and inflammatory markers: a randomised controlled trial. Eur J Nutr 56 (2016), 1421–1432, 10.1007/s00394-016-1188-y.
37. Bezin, J., Francis, F., Nguyen, N.V., et al. Impact of a public media event on the use of statins in the French population. Arch Cardiovasc Dis 110 (2017), 91–98.
38. Rigacci, S., Stefani, M., Nutraceutical properties of olive oil polyphenols: an itinerary from cultured cells through animal models to humans. Int J Mol Sci, 17, 2016, e843.